Details for Patent: 8,835,394

Title:	Treatment for basal cell carcinoma
Abstract:	The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.
Inventor(s):	Owens; Mary L. (Cottage Grove, MN), Fox; Terrance L. (Oakdale, MN), Ginkel; Angela M. (St. Paul, MN)
Assignee:	Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Filing Date:	Oct 18, 2011
Application Number:	13/276,068
Claims:	1. A method of treating basal cell carcinoma in a subject, the method consisting essentially of administering to the subject an amount of an Immune Response Modifier (IRM) compound effective for treating basal cell carcinoma, wherein administering the IRM compound comprises topically applying the IRM compound to a treatment area that includes a lesion, and wherein the IRM compound is administered in a treatment cycle that comprises five consecutive days in which the IRM compound is administered and at least two consecutive days in which the IRM compound is not. 2. The method of claim 1 wherein the method comprises at least two treatment cycles. 3. The method of claim 2 wherein the method comprises at least six treatment cycles. 4. The method of claim 1 wherein administering the IRM compound comprises applying one dose of the IRM compound per day. 5. The method of claim 1 wherein the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound. 6. The method of claim 5 wherein the formulation comprises about 5% IRM compound. 7. The method of claim 5 wherein the formulation is applied to the treatment area for from about two hours to about 24 hours. 8. The method of claim 7 wherein the formulation is applied to the treatment area for from about six hours to about twelve hours. 9. The method of claim 5 wherein the formulation is applied to the treatment area for about eight hours. 10. The method of claim 1 wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion. 11. The method of claim 1 wherein the IRM compound is a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring. 12. The method of claim 1 wherein the IRM compound is imiquimod.